People may seek them out without proper medical guidance
As patent protections fall away from one of the world's most sought-after weight-loss medications, India finds itself at a familiar crossroads between pharmaceutical promise and public health peril. Semaglutide, once priced beyond the reach of most, is poised to become widely affordable — and Indian regulators, anticipating a fivefold market expansion by 2030, are moving to build guardrails before the flood arrives. The Indian Pharmacopoeia Commission has been charged with systematic adverse event tracking, while state drug controllers have been mobilized against misleading advertising targeting those least able to protect themselves. It is the enduring tension of modern medicine: the same force that democratizes access can, without vigilance, democratize harm.
- Semaglutide's patent expiration has triggered a regulatory emergency in India, with generic versions set to transform a ₹1,500 crore market into an ₹8,000 crore one within four years.
- Authorities are alarmed by early signs of misuse — surrogate advertising and unsupervised use of prescription-only drugs — prompting a formal advisory from the Central Drugs Standard Control Organisation in March.
- The Drug Consultative Committee has responded with a three-pronged strategy: tightened state-level enforcement, strict marketing compliance, and mandatory monthly adverse event reporting by the Indian Pharmacopoeia Commission.
- Vulnerable populations remain the central concern, as cheaper generics may flow through informal channels and online retailers to people without medical guidance on a drug that carries real risks including pancreatitis and thyroid complications.
- India is racing to establish institutional guardrails before generic semaglutide becomes as commonplace as over-the-counter medicine — a race whose outcome will become clear within the next two years.
India's drug regulators are preparing for a wave of weight-loss medication use that could fundamentally reshape the country's pharmaceutical market. Last month, semaglutide — the active ingredient in leading obesity drugs — lost its patent protection, opening the door to affordable generics. In response, the Indian Pharmacopoeia Commission has been assigned a pointed new task: compiling monthly or bi-monthly reports on adverse events linked to these medications, a signal that New Delhi intends to catch problems before they take root across a population that may seek out these drugs without medical supervision.
The scale of what's coming is striking. Analysts project the semaglutide segment will grow from roughly ₹1,500 crore today to ₹8,000 crore by 2030 — a fivefold expansion driven by both the drug's effectiveness and India's deepening obesity challenge. Millions who could never afford brand-name pricing will soon have access to a powerful medication, and the government sees opportunity and risk in equal measure.
The regulatory response took shape at a recent Drug Consultative Committee meeting, where officials outlined a coordinated strategy. State and local drug controllers have been ordered to monitor for violations — ensuring companies market these drugs only for approved uses and avoid manipulative advertising aimed at vulnerable populations. Enforcement has been given real authority: states can act against significant violations and must report findings to the central regulator. Meanwhile, the Indian Pharmacopoeia Commission will systematize side-effect tracking to build a clearer picture of real-world outcomes.
The urgency is not hypothetical. In March, the Central Drugs Standard Control Organisation issued an advisory flagging concerns about how weight-loss drugs were being promoted, including through surrogate advertising that skirted rules governing prescription-only medicines. That advisory was a warning shot; the committee meeting was the follow-up.
What troubles regulators most is the gap between availability and guidance. GLP-1 receptor agonists are effective but carry genuine risks — nausea, vomiting, pancreatitis, thyroid concerns — that multiply when people self-medicate without oversight. India is trying to avoid the trajectory seen in wealthier countries, where these drugs became cultural phenomena obtained outside proper medical channels. Whether the regulatory apparatus can keep pace with demand once generic semaglutide becomes widely affordable remains the defining question of the next two years.
India's drug regulators are bracing for a surge in weight-loss medication use that could reshape the country's pharmaceutical landscape. Last month, semaglutide—the active ingredient in popular obesity drugs—lost its patent protection, meaning generic versions will soon flood the market at a fraction of current prices. The Indian Pharmacopoeia Commission, a health ministry body responsible for setting drug quality and safety standards, has been tasked with a new responsibility: compiling monthly or bi-monthly reports on adverse events linked to these medications. The move signals New Delhi's determination to catch problems early, before they spread across a population that regulators worry may seek out these drugs without proper medical supervision.
The numbers tell the story of what's coming. Market researchers project the semaglutide segment will explode from roughly ₹1,500 crore today to ₹8,000 crore by 2030. That five-fold expansion reflects both the drug's effectiveness and the scale of India's obesity challenge. But it also means millions of people could soon have access to a powerful medication that was previously available only to those who could afford brand-name pricing. The government sees opportunity and risk in equal measure.
The regulatory response crystallized in a recent meeting of the Drug Consultative Committee, where officials outlined a three-part strategy. First, state and local drug controllers across India have been ordered to watch closely for violations—ensuring that companies market these drugs only for approved uses, follow labeling rules, and avoid the kind of manipulative advertising that might lure people who shouldn't be taking them. The concern is specific: vulnerable populations, those least equipped to navigate medical decisions independently, could be targeted by misleading promotions. Second, the committee emphasized that enforcement must have teeth. States now have authority to take action against significant violations and must report what they find back to the central regulator. Third comes the surveillance piece: the Indian Pharmacopoeia Commission will systematize the tracking of side effects, creating a clearer picture of what's actually happening in the real world once these drugs are in widespread use.
The urgency reflects a problem that has already surfaced. In March, the Central Drugs Standard Control Organisation issued an advisory flagging concerns about how weight-loss drugs were being promoted and advertised—practices that appeared to violate India's drug laws. Some companies were using surrogate advertising, a technique where a product is promoted indirectly, skirting rules that govern prescription-only medicines. The advisory was a warning shot. The subsequent committee meeting was the follow-up.
What worries regulators most is the gap between availability and guidance. As these drugs become cheap and accessible, people may obtain them through informal channels, online retailers, or without consulting a doctor about whether they're appropriate for their particular health situation. GLP-1 receptor agonists are powerful tools—they work by mimicking a hormone that regulates appetite and blood sugar—but they're not risk-free. Side effects can include nausea, vomiting, pancreatitis, and thyroid concerns. In the hands of someone self-medicating without medical oversight, the calculus changes.
The Indian government is essentially trying to prevent a repeat of what has happened in wealthier countries, where weight-loss drugs have become cultural phenomena, sometimes prescribed for people who don't strictly need them, sometimes obtained without prescriptions at all. India's regulatory apparatus is moving to establish guardrails before the flood arrives. Whether those guardrails will hold once generic semaglutide becomes as common and affordable as aspirin remains an open question. The next two years will tell whether the system can keep pace with demand.
Citas Notables
The government is working to ensure safety issues are identified, documented, and acted on in timely manner.— Senior government official to Economic Times
Vulnerable populations must not be exploited through misleading or manipulative promotional practices.— Drug Consultative Committee emphasis
La Conversación del Hearth Otra perspectiva de la historia
Why does the government care so much about this particular drug? It's not like it's dangerous in the way, say, opioids are.
It's not about the drug itself being inherently dangerous—it works. The worry is about scale and access. When something becomes cheap and widely available, the people using it change. You go from patients carefully selected by doctors to anyone who can afford it, including people who might not actually need it or who might have conditions that make it risky.
So it's a problem of too much of a good thing?
Partly. But also a problem of information asymmetry. These are prescription-only medicines for a reason. They require medical judgment. Once they're generic and cheap, that judgment gets bypassed. Someone sees an ad, buys it online, takes it without talking to anyone. That's where the vulnerability comes in.
The source mentions vulnerable populations specifically. Who are they worried about?
People without access to good medical advice, people who might be persuaded by misleading advertising, people who might use the drug for reasons beyond what it's approved for. In India, that could mean a lot of people. The regulators are trying to prevent companies from exploiting that gap.
Is this about stopping people from using the drug, or about making sure they use it safely?
The latter, officially. But there's tension there. If you make it too hard to access, you're limiting people who genuinely need it. If you don't regulate it enough, you risk harm. The government is trying to thread that needle—keep it available but controlled, monitored, not marketed recklessly.
What happens if the surveillance system finds a real problem?
That's the point of the monthly reports. If adverse events start clustering around certain populations or certain uses, regulators can act—pull approvals, restrict distribution, issue warnings. The system only works if it's actually watching and willing to act fast.